Expression of class III β tubulin in cervical cancer patients administered preoperative radiochemotherapy: Correlation with response to treatment and clinical outcome

Gynecologic Oncology

Volumn 104, Issue 2, 2007, Pages 326-330

  Ferrandina, Gabriella ^a,b   Martinelli, Enrica ^a   Zannoni, Gian Franco ^a   Distefano, Mariagrazia ^a   Paglia, Amelia ^a   Ferlini, Cristiano ^a,b   Scambia, Giovanni ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

III tubulin; Cervical cancer; Prognosis

Indexed keywords

BETA TUBULIN; CISPLATIN; FLUOROURACIL; POLYCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PREOPERATIVE CARE; TREATMENT OUTCOME; TUBULIN; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 33846366042     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.08.046     Document Type: Article

References (39)

1. Keys H.M., Bundy B.N., Stehman F.B., Muderspach L.I., Chafe W.E., Suggs C.L., et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. New Eng. J. Med. 340 (1999) 1154-1161
2. Morris M., Eifel P.J., Lu J., Grigsby P.W., Levenbach C., Stevens R.E., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. New Eng. J. Med. 340 (1999) 1137-1143
3. Whitney C.W., Sauser W., Bundy B.N., Malfetano J.H., Hannigan E.V., Fowler W.C., et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J. Clin. Oncol. 17 (1999) 1339-1348
4. Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. New Eng. J. Med. 340 (1999) 1144-1153
5. Pearcy R., Brundage M., Drouin P., Jeffrey J., Johnston D., Lukka H., et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J. Clin. Oncol. 20 (2002) 966-972
6. Green J., Kirwan J., Tierney J., Symonds P., Fresco L., Williams C., et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst. Rev. 3 (2005) (CD002225)
7. Jurado M., Martinez-Monge R., Garcia-Foncillas J., Azinovic I., Aristu J., Lopez-Garcia G., et al. Pilot study of concurrent cisplatin, 5-fluorouracil, and external beam radiotherapy prior to radiotherapy in locally advanced cervical cancer. Gynecol. Oncol. 74 (1999) 30-37
8. Mancuso S., Smaniotto D., Benedetti Panici P., Favale B., Greggi S., Manfredi R., et al. Phase I-II trial of preoperative chemoradiation in locally advanced cervical carcinoma. Gynecol. Oncol. 78 (2000) 324-328
9. Distefano M., Fagotti A., Ferrandina G., Fanfani F., Smaniotto D., D'Agostino G., et al. Preoperative chemoradiotherapy in locally advanced cervical cancer: long term outcome and complications. Gynecol. Oncol. 99 (2005) S166-S170
10. Houvenaegel G., Lelievre L., Gonzague-Casabianca L., Buttarelli M., Moutardier V., Goncalves A., et al. Long-term survival after concomitant chemoradiotherapy prior to surgery in advanced cervical carcinoma. Gynecol. Oncol. 100 (2006) 338-343
11. Ferrandina G., Ranelletti F.O., Legge F., Lauriola L., Smaniotto D., Margariti P., et al. Cyclo-oxygenase-2 (COX-2) expression in locally advanced cervical cancer patients undergoing chemoradiation plus surgery. Int. J. Radiat. Oncol. Biol. Phys. 55 1 (2003) 21-27
12. Ferrandina G., Ranelletti F.O., Legge F., Gessi M., Salutari V., Distefano M., et al. Prognostic role of the ratio between cyclooxygenase-2 in tumor and stroma compartments in cervical cancer. Clin. Cancer Res. 10 9 (2004) 3117-3123
13. Okumura H., Natsugoe S., Matsumoto M., Mataki Y., Takatori Y., Istigami S., et al. The predictive value of p53, p53R2, ad p21 for the effect of chemoradiation therapy on oesophageal squamous cell carcinoma. Br. J. Cancer 92 (2005) 284-289
14. Chang H.J., Jung K.E., Kim D.Y., Jeong S.Y., Choi H.S., Kim Y.H., et al. Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma. Hum. Pathol. 36 (2005) 364-371
15. O'Rourke D., Kao G.D., Singh N., Park B.W., Muschel R.J., Wu C.J., et al. Conversion of a radio-resistant phenotype into a more sensitive one by disabling erbB receptor signalling in human cancer cells. Proc. Natl. Acad. Sci. 95 (1998) 10842-10847
16. Sato N., Mizumoto K., Nakamura M., Ueno H., Minamishima Y.A., Farber J.L., et al. A possible role of centrosome overduplication in radiation-induced cell death. Oncogene 19 (2000) 5281-5290
17. Matsumoto Y., Hayashi K., and Nishida E. Cyclin-dependent kinase 2 (cdk2) is required for centrosome duplication in mammalian cells. Curr. Biol. 9 (1999) 429-432
18. Allal A., Kahne T., Reverdin A., Lippert H., Schlegel W., and Reymond M.A. Radioresistance-related proteins in rectal cancer. Proteomics 4 (2004) 2261-2269
19. Ferrandina G., Zannoni G.F., Martinelli E., Gallotta V., Mozzetti S., Scambia G., et al. Class III β tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin. Cancer Res. 12 9 (2006) 2774-2779
20. Mozzetti S., Ferlini C., Concolino P., Filippetti F., Raspaglio G., Prislei S., et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin. Cancer Res. 11 1 (2005) 298-305
21. Bernard-Marty C., Treilleux I., Dumontet C., Cardoso F., Fellons A., Gancberg D., et al. Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clin. Breast Cancer 3 5 (2002) 341-345
22. Dumontet C., Isaac S., Souquet P.J., Bejui-Thivolet F., Pacheco Y., Peloux N., et al. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 92 2 (2005) 25-30
23. Seve P., Isaac S., Tredan O., Souquet P.J., Pacheco Y., Perol M., et al. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin. Cancer Res. 11 15 (2005) 5481-5486
24. Wagner K.D., Wagner N., Wellmann S., Schley G., Bondke A., Theres H., et al. Oxygen-regulated expression of the Wilms' tumor suppressor Wt1 involves hypoxia-inducible factor-1 (HIF-1). FASEB J. 17 10 (2003) 1364-1366
25. Kaluz S., Kaluzova M., and Stanbridge E.J. Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SP1 activity. Identification of a novel type of hypoxia-responsive enhancer. Cancer Res. 63 5 (2003) 917-922
26. Brahimi-Horn C., Berra E., and Pouyssegur J. Hypoxia: the tumor's gateway to progression along the angiogenic pathway. Trends Cell. Biol. 11 11 (2001) 32-36
27. Rofstad E.K., Sundford K., Lyng H., and Trope C.G. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis. Br. J. Cancer 83 (2000) 354-358
28. Höckel M., Schlenger K., Höckel S., and Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 59 (1999) 4525-4528
29. Ferrandina G, Distefano M, Smaniotto D, Morganti A, Paglia A, Macchia G, Corvari, Lorusso D., Scambia G. Anemia in patients with locally advanced cervical carcinoma administered preoperative radio-chemotherapy: association with pathological response to treatment and clinical outcome. Gynecol. Oncol. (in press) [Electronic publication ahead of print].
30. World Health Organization. WHO handbook for reporting results of cancer treatment. WHO, Geneva, Offset publication no. 48 (1979) 16-21
31. Piver M.S., Rutledge F., and Smith J.P. Five classes of extended hysterectomy for women with cervical cancer. Obstet. Gynecol. 44 (1974) 265-272
32. Kaplan E., and Meyer P. Non parametric estimation from incomplete observations. J. Am. Stat. Assoc. 53 (1958) 457-481
33. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50 (1966) 163-170
34. Cox D.R. Analysis of binary data (1970), Methven, London
35. Cox D.R. Regression models and life tables. J. Royal Stat. Soc. 34 (1972) 197-220
36. Chakravarthy A.B., Kelley M.C., McLarenB TruicaC.I., Billheimer D., Mayer I.A., Grau A.M., et al. Neoadjuvant concurrent paclitaxel and radiation in stage II/III breast cancer. Clin. Cancer Res. 12 (2006) 1570-1576
37. Miglietta L., Franzone P., Centurioni M.G., Boni L., Tacchini L., Cosso M., et al. A phase II trial with cisplatin-paclitaxel cytotoxic treatment and concurrent external and endocavitary radiation therapy in locally advanced or recurrent cervical cancer. Oncology 70 (2006) 19-24
38. Nabell L., and Spencer S. Docetaxel with concurrent radiotherapy in head and neck cancer. Semin. Oncol. 30 (2003) 89-93
39. Ferlini C., Raspaglio G., Filippetti F., Mozzetti S., Riva A., Manzotti C., et al. Class III β tubulin is transcriptionally regulated by hypoxia and HIF-1 alpha. Proc Am Assoc Cancer Res abstr 2350, 97th Annual Congress, Washington DC (April 2006)